 |
21 Diseases |  |
0 Trials |
|
0 Trials |  |
11 News |  |
- ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Trial primary completion date: ViZIR: Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (clinicaltrials.gov) - Jul 12, 2017
P3, N=0, Withdrawn, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Mar 2017 --> Apr 2014
- ||||||| ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion: Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471) (clinicaltrials.gov) - Apr 3, 2017
P3, N=4469, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Mar 2017 --> Apr 2014 Active, not recruiting --> Completed
- Pegintron/Rebetol Combo Pack (peginterferon alfa-2b + ribavirin) / Merck (MSD), ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Trial completion: HCV Treatment in HIV Co-Infected Patients in Asia (clinicaltrials.gov) - Oct 27, 2016
P4, N=188, Completed, Sponsor: amfAR, The Foundation for AIDS Research
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Pegintron/Rebetol Combo Pack (peginterferon alfa-2b + ribavirin) / Merck (MSD), ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Enrollment closed: HCV Treatment in HIV Co-Infected Patients in Asia (clinicaltrials.gov) - Mar 5, 2015
P4, N=188, Active, not recruiting, Sponsor: amfAR, The Foundation for AIDS Research
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Pegintron/Rebetol Combo Pack (peginterferon alfa-2b + ribavirin) / Merck (MSD), ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Trial primary completion date: HCV Treatment in HIV Co-Infected Patients in Asia (clinicaltrials.gov) - Jan 18, 2015
P4, N=200, Recruiting, Sponsor: amfAR, The Foundation for AIDS Research
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Jun 2016
- ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Enrollment change, Trial withdrawal: ViZIR: Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (clinicaltrials.gov) - Jul 23, 2014
P3, N=0, Withdrawn, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Jan 2016 --> Jun 2016 N=520 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
New P3 trial: ViZIR: Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (clinicaltrials.gov) - Mar 27, 2014
P3, N=520, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- Pegintron/Rebetol Combo Pack (peginterferon alfa-2b + ribavirin) / Merck (MSD), ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Trial initiation date: HCV Treatment in HIV Co-Infected Patients in Asia (clinicaltrials.gov) - Mar 11, 2014
P4, N=200, Recruiting, Sponsor: amfAR, The Foundation for AIDS Research
N=520 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Sep 2013 --> Dec 2013
- Pegintron/Rebetol Combo Pack (peginterferon alfa-2b + ribavirin) / Merck (MSD), ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Enrollment open: HCV Treatment in HIV Co-Infected Patients in Asia (clinicaltrials.gov) - Mar 11, 2014
P4, N=200, Recruiting, Sponsor: amfAR, The Foundation for AIDS Research
Initiation date: Sep 2013 --> Dec 2013 Not yet recruiting --> Recruiting
- | Pegintron/Rebetol Combo Pack (peginterferon alfa-2b + ribavirin) / Merck (MSD), ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
New P4 trial: HCV Treatment in HIV Co-Infected Patients in Asia (clinicaltrials.gov) - Apr 22, 2013
P4, N=200, Recruiting, Sponsor: amfAR, The Foundation for AIDS Research